Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Jun 1;104(2):447-455.
doi: 10.1016/j.ijrobp.2019.02.002. Epub 2019 Feb 12.

Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Chelsea C Pinnix  1 , Jillian R Gunther  2 , Sarah A Milgrom  2 , Ruben J Cruz Chamorro  3 , L Jeffrey Medeiros  4 , Joseph D Khoury  4 , Behrang Amini  5 , Sattva Neelapu  6 , Hun J Lee  6 , Jason Westin  6 , Nathan Fowler  6 , Loretta Nastoupil  6 , Bouthaina Dabaja  2
Affiliations
Comparative Study

Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Chelsea C Pinnix et al. Int J Radiat Oncol Biol Phys. .

Abstract

Purpose: In patients with gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma, the standard radiation therapy (RT) dose is ≥30 Gy. We report the outcome of patients treated with reduced dose 24 Gy compared with those treated with ≥30 Gy.

Methods and materials: We reviewed results from 32 patients who received a diagnosis of gastric MALT lymphoma between 2007 and 2017 who were treated with involved site RT using intensity modulated radiation therapy (IMRT). Response to therapy was based on post-RT endoscopic biopsy. Freedom from local treatment failure (FFLTF), freedom from treatment failure (FFTF), and overall survival (OS) outcomes were determined.

Results: The median age of patients at diagnosis was 58 years. Therapy for MALT was given prior to RT in 14 patients with residual biopsy proven disease documented in all cases (anti-microbial, n=11; rituximab, n=2; rituximab, cyclophosphamide, doxorubicin, vincristine, n=1). One patient received RT (36 Gy) and concurrent rituximab. The median RT dose was 30 Gy; it was 30 to 36 Gy in 66% of patients (n = 21) and 24 Gy in 34% of patients (n = 11). Post-RT biopsy documented a complete response in all patients. Failures occurred in the stomach and duodenum, respectively, at 3.6 and 4.5 years, after 30 Gy. At a median follow-up of 55.2 months (73.8 for ≥30 Gy compared with 28.7 for 24 Gy; P < .001), the 2-year FFLTF, FFTF, and OS were 100%, 100%, and 97%, respectively. No association was found between the lower (24-Gy) dose and FFLTF (P = .819), FFTF (P = .819), or OS (P = .469).

Conclusions: Contemporary RT with involved site targeting using IMRT is associated with high complete response rates for patients with gastric MALT lymphoma, even using reduced doses of 24 Gy. Additional follow-up and increased patient numbers are required to confirm equivalent disease control.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Treatment outcomes after radiation therapy among all patients
Freedom from local treatment failure (FFLTF, a), freedom from treatment failure (FFTF, b) and overall survival (OS, c) among 32 patients treated with definitive RT for gastric MALT lymphoma.
Figure 2.
Figure 2.. Treatment outcomes after radiation therapy among patients according to radiation dose
Freedom from local treatment failure (FFLTF, a), freedom from treatment failure (FFTF, b) and overall survival (OS, c) among 21 patients treated with definitive RT for gastric MALT lymphoma to a standard dose of 30–36 Gy compared to 11 patients that were treated with reduced-dose RT (24 Gy).
See this image and copyright information in PMC

References

    1. Ferreri AJ, Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol 2007;63:245–56. - PubMed
    1. Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (malt lymphoma). CA Cancer J Clin 2016;66:153–71. - PubMed
    1. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric malt lymphoma after eradication of helicobacter pylori: A multicentre cohort follow-up study of 420 patients in japan. Gut 2012;61:507–13. - PubMed
    1. Teckie S, Qi S, Chelius M, et al. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. Ann Oncol 2017;28:1064–1069. - PMC - PubMed
    1. Abe S, Oda I, Inaba K, et al. A retrospective study of 5-year outcomes of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to helicobacter pylori eradication therapy. Jpn J Clin Oncol 2013;43:917–22. - PubMed

Publication types

MeSH terms